The Phase 4, randomized, open-label, parallel-group TRANSITION study (N=1002) evaluated the safety and tolerability of Entresto in HFrEF patients after they were stabilized following an acute heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results